Autoren: Giannitsis E, Clifford P, Slagman A, Ruedelstein R, Liebetrau C, Hamm C, Honnart D, Huber K, Vollert J, Simonelli C, Schröder M, Wiemer J, Mueller-Hennessen M, Schroer H, Kastner K, Möckel M
Source: http://dx.doi.org/10.1136/bmjopen-2018-028311
Indication: Cardiology
Access: Open Access
Product: Copeptin

Autoren: Thomas Reinhold, Evangelos Giannitsis, Martin Moeckel, Lutz Frankenstein, Mehrshad Vafaie, Joern O. Vollert, Anna Slagman
Source: https://doi.org/10.1371/journal.pone.0202133
Indication: Cardiology
Product: Copeptin

The combined copeptin/cTN testing has the potential to save costs and staff time in acute care and for the entire hospital stay. The primary explanations for these findings are early identification and ruling out patients without AMI along with the associated reduced need for acute medical treatment.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0202133 >

Autoren: Morawiec B, Kawecki D, Przywara-Chowaniec B, Opara M, Muzyk P, Ho L, Tat LC, Gabrysiak A, Muller O and Nowalany-Kozielska E
Source: Dis Markers 2018;2018 6597387.
Indication: Cardiology
Access: Open Access
Product: Copeptin

Copeptin appears to be an independent predictor of long-term mortality in a selected population of patients suspected for an ACS.
https://www.ncbi.nlm.nih.gov/pubmed/29619130 >